Hudson Bay Capital Management
BDTX icon

Hudson Bay Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Hudson Bay Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,440
Closed -$25.9K – 1264
2025
Q2 		$25.9K Buy
+10,440
New +$20.1K ﹤0.01% 1295
2022
Q2 		– Sell
-130,000
Closed -$360K – 1334
2022
Q1 		$360K Buy
+130,000
New +$475K ﹤0.01% 891

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management's BDTX Position: Q3 2025 in Review

Hudson Bay Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q3 2025, closing a stake of 10,440 shares — an estimated $25.9K sold.

Hudson Bay Capital Management first reported a position in BDTX in Q1 2022 and held it in 2 quarters. The position peaked at $360K in Q1 2022. 91 funds tracked by Wall St. Rank hold BDTX as of Q3 2025.

  • Hudson Bay Capital Management reported no remaining Black Diamond Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 10,440 Black Diamond Therapeutics shares in Q3 2025, an estimated $25.9K.
  • Hudson Bay Capital Management first reported a position in Black Diamond Therapeutics in Q1 2022 and held it in 2 quarters.
  • Hudson Bay Capital Management's Black Diamond Therapeutics position peaked at $360K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q3 2025.

Based on Hudson Bay Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.